AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo, Inc. - Cases and Conversations – Evolving Radiation Strategies in HER2-Positive Breast Cancer: Early-Stage Through Metastatic Disease

session DESCRIPTION

This hybrid educational activity is directed towards ASTRO attendees, including an audience of radiation oncologists, medical and surgical oncologists, advanced practice providers, nurses, and other healthcare professionals managing HER2-positive breast cancer. Dinner will be provided. For more information, please visit the Industry Satellite Symposia page.

learning objectives

1. Evaluate the safety profile of concurrent and sequential radiation therapy with T-DXd, including strategies to distinguish drug-related ILD from radiation pneumonitis.

2. Develop a radiation treatment plan that accounts for the overlapping pulmonary and cardiac toxicity risks of ADC-based systemic therapy in HER2-positive breast cancer.

3. Assess the implications of recent and emerging clinical trial data for the role of radiation therapy in early-stage and metastatic HER2-positive breast cancer.

4. Apply a multidisciplinary framework to integrate systemic and local therapy for HER2-positive breast cancer with brain metastases.